Enhertu approved in US for HER2+ solid tumours
08 April 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
for previously treated patients with metastatic HER2-positive solid tumours
Based on…
60,250€
-4,37%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AstraZenecas (AZN) Enhertu Gets FDA Nod for Solid Tumors
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyos Enhertu for HER2-expressing metastatic cancers based on data from three phase II…
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors By Reuters
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors…
Astrazeneca: Wichtiges Medikament erreicht Ziele in Lungenkrebsstudie
CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in einer abschließenden klinischen Studie (Phase-III) mit Lungenkrebs-Patienten einen Erfolg erzielt. Das…
Imfinzi improved OS & PFS in limited-stage SCLC
05 April 2024
Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase…
AstraZenecas (AZN) Imfinzi Improves Survival in SCLC Study
AstraZenecas (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase…
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
FDA approves AstraZenecas (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck…
Total Voting Rights
2 April 2024 15:00 BST
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
FDA accepts Dato-DXd BLA for breast cancer
2 April 2024
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
AstraZenecas (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.…